Biomaterials research最新文献

{"title":"A Tumor-Responsive Enzymatic Cascade System Inducing pH-Activable Metabolic Starvation and H₂O₂-Induced Apoptosis.","authors":"Junyoung Jung, Jae Hun Lee, Seoungkyun Kim, Kiyoon Kwon, Giyoong Tae, Inchan Kwon","doi":"10.34133/bmr.0380","DOIUrl":"10.34133/bmr.0380","url":null,"abstract":"<p><p>Conventional tumor-targeted therapies primarily focus on drug delivery systems exploiting the tumor microenvironment for controlled drug release. While prodrug strategies activate small-molecule drugs in tumors, they rely on single-step chemical conversions and lack sustained tumor-selective activity. Here, a novel strategy of tumor-responsive, enzymatic cascade therapy is introduced by co-delivering arginine decarboxylase (RDC) and diamine oxidase (DAO) into the tumor site. Unlike traditional arginine depletion strategies, RDC remains inactive at physiological pH and is selectively activated under acidic tumor conditions, ensuring localized metabolic starvation while minimizing systemic toxicity. To overcome a key limitation of RDC-namely, the accumulation of toxic agmatine-RDC is co-delivered with DAO using a chitosan-functionalized Pluronic-based nanocarrier (RDC/DAO@NC), enabling tumor-specific conversion of agmatine into hydrogen peroxide (H₂O₂). This pH-sensitive cascade reaction is expected to limit agmatine accumulation in normal tissues while amplifying RDC-mediated antitumor effects through oxidative-stress-induced apoptosis. In vitro, RDC/DAO@NC suppresses tumor cell proliferation through arginine depletion and induces apoptosis via H₂O₂ generation. In vivo, RDC/DAO@NC substantially enhances tumor accumulation and therapeutic efficacy compared to free enzymes. This study provides the first in vivo validation of RDC-based cancer therapy, suggesting its potential as a tumor-selective strategy integrating enzyme activation in the tumor microenvironment, metabolic starvation, and reactive-oxygen-species-induced apoptosis in cancer treatment.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0380"},"PeriodicalIF":9.8,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13247311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineering Glioma-Cell-Derived Exosomes as Trojan Horse for Precisely Targeted Chemotherapy of Glioblastoma.","authors":"Zhijun He, Zhe Meng, Guoxi Luan, Pengbo Li, Chunyi Yang, Yifan Liang, Xiaodan Sun, Lingyun Zhao, Guihuai Wang, Xiumei Wang","doi":"10.34133/bmr.0365","DOIUrl":"10.34133/bmr.0365","url":null,"abstract":"<p><p>The management of glioblastoma multiforme (GBM) remains challenging due to its poor prognosis and extremely high postoperative recurrence rate. Although the Gliadel wafer locally delivers carmustine, its clinical application is limited by suboptimal therapeutic efficacy and poor conformability to irregular resection cavities. To overcome these limitations, we developed a novel drug delivery system based on thermosensitive injectable chitosan-β-glycerol phosphate hydrogel containing doxorubicin-loaded mesoporous silica nanoparticles encapsulated within tumor-derived exosomes (Exo-DMSNs@CS). In an orthotopic mouse GBM relapse model recapitulating clinical tumor resection, the liquid Exo-DMSNs@CS formulation was injected into the surgical cavity and subsequently gelated in situ, achieving seamless adhesion to the irregular resection margins of the cavity. The exosome-coated nanoparticles (Exo-DMSNs), released gradually from chitosan hydrogel, exhibited enhanced tumor-targeting capability via exosome-mediated tumor-homing performance, thereby substantially promoting drug internalization. Compared to non-exosomal controls (DMSNs@CS), Exo-DMSNs@CS markedly suppressed tumor recurrence and prolonged survival. Our findings demonstrate that this Trojan-horse-inspired delivery strategy-leveraging tumor-derived exosomes to encapsulate drug-loaded nanoparticles-enables a localized and precise tumor-targeted drug delivery system, representing a promising therapeutic paradigm for GBM treatment.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0365"},"PeriodicalIF":9.8,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13226992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148159539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroblast Growth Factor 2-Immobilized Biointerfaces Drive Exogenous Transforming Growth Factor β1-Independent Chondrogenesis of Human Mesenchymal Stem Cell and Ectopic Cartilage Tissue Formation.","authors":"Ji Hoon Jeong, Jae Hong Park, Myung Jin Ban, Yeongrok Lee, Hyeongtae Kim, Yura Kim, Gahyun Kim, Sai-Won Kwon, Ju Hun Lee, Sang-Heon Kim, Yongsung Hwang","doi":"10.34133/bmr.0367","DOIUrl":"10.34133/bmr.0367","url":null,"abstract":"<p><p>Articular cartilage regeneration remains challenging due to limited intrinsic repair capacity and the tendency of current human mesenchymal stem cell (hMSC)-based strategies to form fibrocartilage or undergo hypertrophy. Here, we present a defined biomaterial platform in which maltose-binding protein-fibroblast growth factor 2 (MBP-FGF2) is surface-immobilized to create a bioinstructive interface that directs in vitro hMSC chondrogenesis without exogenous transforming growth factor-β1 (TGF-β1). The immobilized FGF2 interface promotes spontaneous, scaffold-free spheroid assembly via FGFR1-heparan sulfate proteoglycan-mediated adhesion, providing localized and sustained signaling. Transcriptomic and molecular analyses revealed early activation of FGF- and TGF-β-related pathways, with up-regulation of SOX9, COL2A1, and aggrecan and suppression of COL1A1 and COL10A1. These effects were consistently observed in hMSCs derived from both human embryonic stem cells and human tonsil tissue. Upon subcutaneous implantation into immunodeficient mice, pre-differentiated spheroids generated ectopic cartilage tissue rich in type II collagen and aggrecan, even in the absence of TGF-β1. Taken together, these findings establish FGF2-immobilized biointerfaces as bioinstructive matrices that enable exogenous TGF-β-independent chondrogenesis and ectopic cartilage tissue formation, providing a defined and reproducible route for generating chondrogenic constructs for regenerative medicine.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0367"},"PeriodicalIF":9.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13223357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro and In Vivo Evaluation of Yttria-Niobia-Stabilized Zirconia Sandblasted Surface at Bone-Implant Interface with 3-Dimensional Visualization via Advanced Hard Tissue Clearing.","authors":"Chae-Ryeong Cha, Young-Sung Kim, Satoshi Imazato, Dae-Joon Kim, Yang-Jo Seol, Chang-Joo Park, In-Sung L Yeo","doi":"10.34133/bmr.0377","DOIUrl":"10.34133/bmr.0377","url":null,"abstract":"<p><p>Titanium is widely acknowledged as the \"gold standard\" for dental implants because of its superior biocompatibility and osseointegration capabilities. However, it is limited by the possibility of metal allergies, aesthetic concerns such as gray discoloration visible through the thin gingiva, and the risk of corrosion. To overcome these limitations, metal-free implant materials, particularly yttria-niobia-stabilized tetragonal zirconia polycrystals ((Y,Nb)-TZP), have attracted increasing attention. Zirconia has been noted for its advantages, including promising mechanical properties, biocompatibility, aesthetics, and reduced bacterial adhesion. Despite these findings, comparative studies of sandblasted, large-grit, acid-etched (SLA) titanium and (Y,Nb)-TZP are limited. This study aimed to compare the in vitro osteogenic potential and in vivo osseointegration of sandblasted (Y,Nb)-TZP implants with those of conventional SLA titanium implants using 3-dimensional evaluation. (Y,Nb)-TZP implants demonstrated comparable in vitro and in vivo results to SLA titanium, despite significantly lower surface roughness. Early cell attachment and spreading were observed on (Y,Nb)-TZP, whereas alkaline phosphatase activity and late-stage osteogenic gene expression increased over time in both groups without intergroup differences. In in vivo experiments, no significant between-group differences were observed in bone-to-implant contact, bone area, and dynamic bone remodeling indices. Three-dimensional-based analysis revealed similar overall bone remodeling volumes but distinct spatial distributions of newly formed bone around the implant threads, providing additional insights into the subcortical peri-implant bone area. In conclusion, sandblasted (Y,Nb)-TZP implants exhibited osteogenic potential and osseointegration comparable to those of SLA titanium implants, supporting the potential clinical applicability of (Y,Nb)-TZP as an alternative implant material.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0377"},"PeriodicalIF":9.8,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13223697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Injectable Poloxamer and Hyaluronic Acid Hydrogel for Sustained Co-Delivery of Dexamethasone and Lidocaine Ameliorates Neuropathic Pain.","authors":"Yanting Liu, Seungwoon Baik, Trung Nhan Vo, Songzi Zhang, Boram Kim, Tae-Keun Ahn, Inbo Han, Dong Keun Han","doi":"10.34133/bmr.0373","DOIUrl":"10.34133/bmr.0373","url":null,"abstract":"<p><p>Neuropathic pain is a debilitating condition driven by complex neuro-immune-glial interactions and central sensitization. Current pharmacological interventions, such as opioids and ion channel blockers, are often limited by short half-lives, systemic toxicity, and tolerance. To overcome these barriers, we developed an injectable, thermosensitive hydrogel system based on poloxamer and hyaluronic acid (PLX/HA) for the sustained, localized co-delivery of dexamethasone (Dex) and lidocaine (Lid). In vitro characterization demonstrated that HA incorporation optimized the hydrogel's microstructural porosity, enabling the sustained release of bioactive agents for up to 28 d. At the cellular level, the system marked enhanced neuronal survival under inflammatory stress by modulating the Bax/Bcl-2 apoptotic pathway and suppressing nuclear factor κB (NF-κB) nuclear translocation and cyclooxygenase-2 (COX-2) expression. In a rat model of chronic constriction injury (CCI), the Dex/Lid@PLX/HA formulation provided sustained improvement in mechanical allodynia and thermal hyperalgesia, with greater efficacy than the solution and standard gel control groups at multiple time points. Mechanistically, the therapeutic effects were accompanied by attenuation of TRPV1, CGRP, and SGC activation-related signals, suggesting suppression of peripheral nociceptive sensitization and attenuation of DRG neurodegenerative pathology, including reduced Nageotte nodule-like changes. Furthermore, the PLX/HA system was associated with reduced proinflammatory macrophage infiltration and an increased CD163-positive macrophage signal, suggesting a more reparative local immune microenvironment. This study presents a localized co-delivery strategy with analgesic and anti-inflammatory effects for neuropathic pain management and peripheral nerve protection.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0373"},"PeriodicalIF":9.8,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13216820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Perivascular Adipose Tissue Responses to Bioresorbable Thermoplastic Polyurethane Vascular Grafts.","authors":"Anna-Maria Schmitt, Sabrina Rohringer, Sophie J Specht, Selin Topcu, Christian Grasl, Heinrich Schima, Michael Prückler, Ingrid Walter, Bruno K Podesser, Helga Bergmeister","doi":"10.34133/bmr.0372","DOIUrl":"10.34133/bmr.0372","url":null,"abstract":"<p><p>Substantial progress has been made in developing artificial small-diameter vascular grafts (SDVGs), yet the contribution of perivascular adipose tissue (PVAT) to vascular graft healing remains poorly understood. This study investigated the interaction of biodegradable thermoplastic polyurethane (TPU) SDVGs with PVAT using in vitro and in vivo models. Vascular and perivascular cells were cultured on TPU and analyzed by viability assays, immunofluorescence staining, scanning electron microscopy, quantitative polymerase chain reaction, and secretome and cell lysate analysis. TPU grafts were implanted into male Sprague Dawley rats for 1 week or 3 months (control = sham; <i>n</i> = 6/group) and assessed for cellularization, expression of inflammation-related genes, and adipocyte subtype markers. TPU supported viability, attachment, and phenotype preservation of in vitro-seeded cells. Immunofluorescence staining revealed increased adiponectin expression, and adipokine profiling identified 14 substantially up-regulated adipokines in TPU-seeded PVAT-derived cells. Histology showed rapid cellular coverage of grafts within 1 week of implantation, including CD34⁺ endothelial progenitor cells on the lumen. Quantitative polymerase chain reaction demonstrated compartment-specific dynamics: Inflammatory markers within the grafts changed predominantly after 3 months, whereas adjacent PVAT showed an early response with <i>Tnfa</i> induction already at 1 week. PVAT further displayed evidence of desirable immune modulation, with altered expression of innate (<i>Cd11c</i> and <i>Arg1</i>) and adaptive (<i>Foxp3</i> and <i>Tbet</i>) immune response markers, alongside partial white-to-brown adipocyte remodeling. These findings highlight PVAT's central role-through adipokine secretion, adipocyte browning, and inflammation regulation-in vascular graft healing and underscore the importance of considering PVAT-driven adipokine dynamics in SDVG design to ensure long-term patency.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0372"},"PeriodicalIF":9.8,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13213075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148058959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-senescence Effects of Nanovesicles Derived from Cluster of Differentiation-146-Positive Tonsil Mesenchymal Stem Cells via Modulation of the Tumor Protein 53 Pathway.","authors":"Dohyun Kim, Hong Bae Jeon, Kyu-Sik Shim, Jeong Su Park, Jeong-Kee Yoon, Jun Hee Lee, Jeong-Hui Park, Jang-Hyun Park, Jieun Kim, Jinseo Yoon, Jung Bok Lee, Wooyeol Baek","doi":"10.34133/bmr.0371","DOIUrl":"10.34133/bmr.0371","url":null,"abstract":"<p><p>Aging greatly contributes to the progressive dysfunction of tissues and organs that accompany the aging process. Recently, nanovesicles derived from tonsil mesenchymal stem cells (TMSC-NVs) were investigated for their potential to reverse cellular senescence. However, the molecular mechanisms through which TMSC-NVs prevent senescence remain unclear. In the present study, we focused on Cluster of Differentiation 146 (CD146), a surface marker used to identify specific MSC subgroups and examined the anti-senescence effects of CD146-positive TMSC-NVs (CD146⁺ TMSC-NVs). To evaluate the antisenescence effects of the CD146⁺ TMSC-NVs, passage-associated cellular senescence in vitro human dermal fibroblast model, ultraviolet-B-induced photoaging ex vivo model, and intrinsic aging in vivo mice model were assessed. Microarray analysis, immunofluorescence staining, and miRNA profiling demonstrated the anti-senescence mechanism of CD146⁺ TMSC-NVs through modulation of the p53 pathway, thereby effectively suppressing cellular senescence and matrix metalloproteinase activity and improving extracellular matrix remodeling. These results indicate the anti-senescence effects of CD146⁺ TMSC-NVs for therapeutic approach.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0371"},"PeriodicalIF":9.8,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148019148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Dual-Mechanism Targeted Cross-Convergence Prodrug Activation Strategy Enabled by Biological Stimulus Amplification toward Precision Cancer Therapy.","authors":"Zeyu Wang, Yajie Xing, Dong Wang, Yumeng Niu, Fang Chen, Kun Fan, Xin Meng, Mi Li, Dandan Xia, Lan Wu, Haiyan Xu, Qi Guan, Weige Zhang","doi":"10.34133/bmr.0328","DOIUrl":"10.34133/bmr.0328","url":null,"abstract":"<p><p>Current prodrug strategies in clinical practice still face several challenges, such as insufficient targeting specificity, substantial systemic toxicity, and complex administration protocols, which urgently need to be resolved. Here, we present a dual-mechanism targeted cross-convergence activation strategy, which couples tumor-targeting prodrug delivery with biological stimulus amplification to achieve precise and highly efficient drug release. The system comprises 2 components: (a) <b>BTW2</b> nanoparticles, a reactive oxygen species (ROS)-responsive prodrug conjugated to biotin for tumor-selective accumulation via the enhanced permeability and retention effect and biotin-receptor-mediated uptake, and (b) IR-808, a heptamethine dye that targets tumors through organic-anion-transporting polypeptides and amplifies intracellular ROS. Upon cross-convergence at tumor sites, IR-808 elevates ROS levels, triggering thioketal linker cleavage in <b>BTW2</b> nanoparticles to release <b>W436</b>, a potent tubulin inhibitor. The released <b>W436</b> further amplifies ROS, establishing a self-reinforcing positive feedback loop. This strategy enables precision therapy for primary and metastatic cancers via spatiotemporally controlled, self-reinforcing drug release.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0328"},"PeriodicalIF":9.8,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13187504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147990378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermosensitive Hydrogel Enables Noninvasive Extracellular Vesicle Therapy for Atopic Dermatitis.","authors":"Doil Park, Mingyu Jeon, Jooho Kim, Ji Eun Kim, Yeonjeong Kim, Kyung Min Park, Eun Hee Kim, Jae Min Cha, Oh Young Bang","doi":"10.34133/bmr.0368","DOIUrl":"10.34133/bmr.0368","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by impaired barrier function and helper T cell 2 (Th2)-dominant immune dysregulation. Subcutaneous administration of mesenchymal-stem-cell-derived extracellular vesicles (MSC-EVs) has shown substantial efficacy in preclinical AD models; however, its clinical utility remains restricted by injection-associated pain and poor patient compliance, necessitating more patient-friendly delivery strategies. Here, we propose a patient-friendly, noninvasive therapeutic strategy using clinical-grade MSC-EVs incorporated into a thermosensitive hyaluronic acid/Pluronic F127 (HP) hydrogel. The optimized HP hydrogel exhibited desirable shear-thinning behavior and tunable sol-gel transition at body temperature, enabling sustained EV release. In a <i>Dermatophagoides farinae</i>-extract-induced AD mouse model, topical application of HP-loaded EVs (HP+EVs) suppressed AD symptoms, epidermal thickening, and mast cell infiltration, demonstrating an efficacy comparable to that of subcutaneous EV injections. Notably, HP+EV treatment down-regulated both Th2 and Th1/pro-inflammatory cytokines, restoring their levels to those in healthy controls. In addition, EVs rapidly penetrated the disrupted skin barrier in AD lesions via surface-protein-dependent mechanisms, as evidenced by the loss of permeability following proteinase K treatment. Furthermore, HP+EV treatment up-regulated barrier proteins and markedly down-regulated oxidative stress markers. This study demonstrates a major advancement in EV-based therapeutics, providing a promising noninvasive formulation for the treatment of AD.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0368"},"PeriodicalIF":9.8,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13181167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147977590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomimetic Layered Double Hydroxide-Molybdenum Disulfide Encapsulated with Bovine Serum Albumin: A Multifaceted Nanotherapy for Inflammatory Bowel Disease.","authors":"Yijie Xie, Qiwen Jiang, Huabing Huang, Xinyuan Zhang, Xiaoyi Zheng, Yunyi Yang, Shige Wang, Jiulong Zhao, Zhaoshen Li","doi":"10.34133/bmr.0369","DOIUrl":"10.34133/bmr.0369","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) remains a therapeutic challenge due to its ongoing inflammation and the limited availability of effective local therapies. This study developed a biomimetic nanocomposite, layered double hydroxide-molybdenum disulfide (LDH-MoS₂ [LM]) nanosheets encapsulated with bovine serum albumin (abbreviated as LM@BSA), with the aim of enhancing reactive oxygen species scavenging efficiency and improving colloidal stability while favoring lesion-associated localization and local retention in inflamed colonic tissue. In a dextran sulfate sodium-induced colitis mouse model, oral administration of LM@BSA nanocomposite significantly improved disease outcomes, as shown by reduced colon shortening, less body weight loss, and decreased levels of pro-inflammatory cytokines. Mechanistic analysis demonstrated that the LM@BSA nanocomposite inhibits ferroptosis by protecting mitochondrial structure and increasing glutathione peroxidase 4 expression. Transcriptomic data showed that the LM@BSA nanocomposite helps restore intestinal balance by down-regulating the phosphoinositide 3-kinase-protein kinase B signaling pathway, regulating extracellular matrix remodeling, and supporting immune pathway stability. Moreover, the LM@BSA nanocomposite corrected gut microbiota dysbiosis by increasing the abundance of beneficial <i>Bacteroidales</i> and reducing pro-inflammatory <i>Desulfovibrionales</i>. These findings suggest that the LM@BSA nanocomposite offers a promising and comprehensive multifaceted nanotherapeutic approach for IBD by modulating oxidative stress, ferroptosis, immune dysregulation, and gut microbiota imbalance.</p>","PeriodicalId":93902,"journal":{"name":"Biomaterials research","volume":"30 ","pages":"0369"},"PeriodicalIF":9.8,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13181168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147977501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}